Our mission
Our progress
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
Mereo BioPharma today announced the appointment of Dr. Abdul Mullick to the Company’s Board of Directors, effective immediately.
Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema
09 May 2022
Mereo BioPharma announces positive topline results from ASTRAEUS a Phase 2 trial of alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema.
Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
Mereo BioPharma Group plc today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema.
Navicixizumab Phase 1b Data Has Been Published in the Journal of Clinical Oncology
22 April 2022
Mereo BioPharma's partner for the development of Navicixizumab, OncXerna Therapeutics Inc. announced that Navicixizumab Phase 1b data has been published in the Journal of Clinical Oncology.
Driven by a true understanding of the critical nature of our mission, we harness the power of science and meaningful relationships to create new possibilities for patients who need them.
